Our Technology

We have invented a blood-based non-immune method that can detect pathological structured protein aggregates (so-called amyloid nano-plaques) with the ultimate single-molecule sensitivity and measure their concentration and size.

Minimal Invasive, Rapid and Safe

Our method is: minimally invasive – it is based on blood sample analysis; rapid – results can be obtained within minutes after sample collection; easy to use – plug-and-play instrument with minimal staff training is needed; safe – contrast injection is not needed; environmentally friendly – it is based on a safety approved, non-radioactive substance; cost-effective – it can be used in general healthcare to identify individuals at risk and in patient surveillance, to monitor disease progression and the efficacy of therapeutic interventions.

Sustainability

Our value proposition supports Sustainable Development Goals (SDGs) and is relevant for both patients, their relatives, as well as healthcare systems and national economies. Most notably, AmyloiDia contributes to the following three SDGs:

SDG 3 Good health and well-being Target 3.8:

Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all.

All over the world, the number of elderlies is continuously increasing. Along with, the risk for developing amyloid diseases and Alzheimer’s in particular, is increasing and so are the societal care-associated costs. Our minimally invasive, rapid, and cost-effective blood-based assay for early diagnosis of amyloid diseases can significantly improve this dismal situation. Furthermore, with newly approved anti-amyloid treatments for Alzheimer’s disease, early diagnosis will allow preventive measures to be taken to slow down the cognitive decline and delay the onset of the care-intensive disease phase, improving the quality of life of the patient, his/her relatives, and significantly reducing the costs of care.

SDG 9 Industry, innovation, and infrastructure Target 9.5:

Enhance scientific research, upgrade the technological capabilities of industrial sectors in all countries, in particular developing countries, including, by 2030, encouraging innovation and substantially increasing the number of research and development workers per 1 million people and public and private research and development spending.

AmyloiDia’s technology holds the potential to create new research jobs and contribute to increased employment in the photonics, medical devices, and pharmaceutical industries.

SDG 10 Reduce inequality within and among countries Target 10.3:

Ensure equal opportunity and reduce inequalities of outcome, including by eliminating discriminatory laws, policies and practices and promoting appropriate legislation, policies and action in this regard.

The World Alzheimer Report 2021 shows that 75 percent of all dementia cases go undiagnosed across the globe, and up to 90 percent in low-middle-income-countries
So it is clear that there is a huge unevenness in how Alzheimer’s diseases is diagnosed between countries, and it is also becoming evident that differences exist between regions within high-income countries. These inequalities arise because imaging techniques, such as amyloid-PET (Positron Emission Tomography) rely on the use of short-lived radioisotopes the production of which cannot be readily enmassed. Also, antibodies for immuno-assays are still expensive. An easy and affordable, blood-based diagnosis would reduce the existing inequalities in AD diagnosis within and among countries.

Amyloidia - Ultimate Diagnostics

Contact us

Please contact us for further information and with any questions, we are very happy to help.